Andersen-Tawil syndrome screening: Difference between revisions

Jump to navigation Jump to search
Line 18: Line 18:
* There is insufficient evidence to recommend routine screening for Andersen-Tawil syndrome.
* There is insufficient evidence to recommend routine screening for Andersen-Tawil syndrome.
* But when a patient with positive KCNJ2 mutation and have no symtoms in Andersen-Tawil syndrome yearly screening with the following should be considered:  
* But when a patient with positive KCNJ2 mutation and have no symtoms in Andersen-Tawil syndrome yearly screening with the following should be considered:  
** A 12-lead ECG<ref name="pmid203014412">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K et al.| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=20301441 | doi= | pmc= | url= }}</ref>
** A 12-lead ECG<ref name="pmid203014412">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K et al.| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=20301441 | doi= | pmc= | url= }}</ref><ref name="SpillaneKullmann2015">{{cite journal|last1=Spillane|first1=J|last2=Kullmann|first2=D M|last3=Hanna|first3=M G|title=Genetic neurological channelopathies: molecular genetics and clinical phenotypes|journal=Journal of Neurology, Neurosurgery & Psychiatry|year=2015|pages=jnnp-2015-311233|issn=0022-3050|doi=10.1136/jnnp-2015-311233}}</ref>
** 24-hour Holter monitoring
** 24-hour Holter monitoring



Revision as of 21:09, 30 January 2020

Xyz Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Xyz from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Andersen-Tawil syndrome screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Andersen-Tawil syndrome screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Andersen-Tawil syndrome screening

CDC on Andersen-Tawil syndrome screening

Andersen-Tawil syndrome screening in the news

Blogs on Andersen-Tawil syndrome screening

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Andersen-Tawil syndrome screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

There is insufficient evidence to recommend routine screening for Andersen-Tawil syndrome.

OR

According to the [guideline name], screening for [disease name] is not recommended.

OR

According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].

Screening

  • There is insufficient evidence to recommend routine screening for Andersen-Tawil syndrome.
  • But when a patient with positive KCNJ2 mutation and have no symtoms in Andersen-Tawil syndrome yearly screening with the following should be considered:
    • A 12-lead ECG[1][2]
    • 24-hour Holter monitoring

OR

According to the [guideline name], screening for [disease name] is not recommended.

OR

According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with:

  • [Condition 1]
  • [Condition 2]
  • [Condition 3]

References

  1. Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K; et al. (1993). "GeneReviews®". PMID 20301441.
  2. Spillane, J; Kullmann, D M; Hanna, M G (2015). "Genetic neurological channelopathies: molecular genetics and clinical phenotypes". Journal of Neurology, Neurosurgery & Psychiatry: jnnp-2015–311233. doi:10.1136/jnnp-2015-311233. ISSN 0022-3050.

Template:WH Template:WS